Publications and PresentationsPublications and presentations
June 2022
Novel ultra-potent capsid assembly modulators (CAMs) prevent abnormal accumulation of empty capsids and associated T-cell mediated liver injury in a mouse model of hepatitis B virus (HBV) infection
Presented at the EASL 2022 Meeting
June 2022
Sustained 12 Week Off Treatment Antiviral Efficacy of ATI-2173, a Novel Active Site Polymerase Inhibitor Nucleotide (ASPIN), Combined With Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients, a Phase 2a Clinical Trial
Presented at the EASL 2022 Meeting
May 2022
Active Site Polymerase Inhibitor Nucleotides (ASPINs) for Chronic Hepatitis B Infection
Presented at 2nd Annual Chronic HBV Drug Development Summit
March 2022
Developing a cure for chronic hepatitis B requires a fresh approach
Paper published in Nature.
Approved treatments for chronic infections of hepatitis B virus (HBV) are currently limited to two main types: injections of interferon, a substance normally produced by the immune system to fight infections, and nucleoside or nucleotide analogues (NUCs). NUCs are well-tolerated drugs that can be taken orally to potently suppress virus replication, and are the main therapy for chronic HBV in most countries.
March 2022